Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial

The Lancet Neurology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles